|
Post by brentie on May 12, 2015 16:21:01 GMT -5
MannKind’s “Buy” Rating Reaffirmed at Jefferies Group (MNKD) Jefferies Group reissued their buy rating on shares of MannKind (NASDAQ:MNKD) in a research report sent to investors on Tuesday morning. The firm currently has a $9.00 price target on the stock. MNKD has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. downgraded shares of MannKind from a neutral rating to an underweight rating and lowered their price target for the stock from $7.00 to $4.00 in a research note on Monday. Analysts at MLV & Co. lowered their price target on shares of MannKind from $7.00 to $4.00 and set a hold rating on the stock in a research note on Monday. Analysts at Piper Jaffray initiated coverage on shares of MannKind in a research note on Friday. They set a hold rating and a $3.50 price target on the stock. Finally, analysts at Vetr downgraded shares of MannKind from a strong-buy rating to a buy rating and set a $6.37 price target on the stock in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. MannKind presently has an average rating of Hold and an average price target of $7.16. Shares of MannKind (NASDAQ:MNKD) traded up 1.93% on Tuesday, hitting $3.70. 6,310,393 shares of the company’s stock traded hands. MannKind has a 52-week low of $3.46 and a 52-week high of $11.48. The stock’s 50-day moving average is $4. and its 200-day moving average is $5.. The company’s market cap is $1.47 billion. www.lulegacy.com/2015/05/12/mannkinds-buy-rating-reaffirmed-at-jefferies-group-mnkd/478688/
|
|
|
Post by jpg on May 12, 2015 17:54:34 GMT -5
Goldman just put out a bit more poison to stop any and all optimism. The are good and as usual perfectly timed.
|
|
|
Post by compound26 on May 12, 2015 18:26:25 GMT -5
|
|
|
Post by jpg on May 12, 2015 18:42:57 GMT -5
No. This is the latest assault:
Goldman Sachs Reaffirms “Sell” Rating for MannKind (MNKD) May 12th, 2015 • 0 comments • Filed Under • by ABMN Staff Tweet MannKind (NASDAQ:MNKD)‘s stock had its “sell” rating reiterated by research analysts at Goldman Sachs in a report released on Tuesday. They currently have a $2.00 price objective on the stock, down from their previous price objective of $3.00. Goldman Sachs’ price objective would indicate a potential downside of 45.21% from the company’s current price.
MannKind (NASDAQ:MNKD) traded up 0.55% during mid-day trading on Tuesday, hitting $3.65. The stock had a trading volume of 8,245,303 shares. MannKind has a one year low of $3.46 and a one year high of $11.48. The stock has a 50-day moving average of $4. and a 200-day moving average of $5.. The company’s market cap is $1.45 billion.
MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, May 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). During the same quarter in the previous year, the company posted ($0.14) earnings per share. On average, analysts predict that MannKind will post $-0.34 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on MNKD. Analysts at Jefferies Group reiterated a “buy” rating and set a $9.00 price target on shares of MannKind in a research note on Tuesday. Analysts at JPMorgan Chase & Co. downgraded shares of MannKind from a “neutral” rating to an “underweight” rating and lowered their price target for the stock from $7.00 to $4.00 in a research note on Monday. Analysts at MLV & Co. lowered their price target on shares of MannKind from $7.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday. Finally, analysts at Piper Jaffray initiated coverage on shares of MannKind in a research note on Friday. They set a “hold” rating and a $3.50 price target on the stock. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.06.
MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The Company’s product candidate is AFREZZA which is an ultra rapid-acting insulin that is intended to improve glycemic control in adults with type 1 or type 2 diabetes.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with Analyst Ratings Network's FREE daily email newsletter.
|
|
|
Post by compound26 on May 12, 2015 18:57:58 GMT -5
Thanks, JPG. I think they refer to the same report (which I believe came out yesterday). One website quoted yesterday and the other quoted today. MannKind 'Facing Low Profitability And Delayed Profits' As Afrezza Ramp Fizzles, Goldman Says Javier Hasse , Benzinga Staff Writer May 11, 2015 3:35pm MannKind Corporation shares fell 5 percent Monday after JP Morgan downgraded the stock from Neutral to Underweight. The demotion followed last Friday’s earnings release, which disappointed many investors and analysts. Jefferies analyst Shaunak Deepak maintained a Buy rating and $9 price target. Analysts at Goldman Sachs reiterated a Sell and trimmed their price target from $3.00 to $2.00, to account for challenging headwinds. The News According to the research note, MannKind's share (Sanofi is a partner) of the Afrezza first quarter loss amounts to $12.4 million, “which was financed by a $175mn loan facility with Sanofi which now stands at $15.4mn. MNKD acknowledged that Afrezza sales were lower than expected and described plans to address certain headwinds including a black box warning on the label that requires spirometry testing and managed care hurdles such as prior authorization. Separately, management anticipates DTC advertising to begin this summer.” The Implications As Goldman Sachs has said in previous occasions, they believe MannKind “is facing low profitability and delayed profits based on a slow ramp of Afrezza, patient-driven market dynamics requiring heavy SG&A spending, and challenging deal terms with Sanofi.” Concerned that Afrezza the sales targets it is required by MannKind (to cover milestone payments to Sanofi), the firm lowered its sales and earnings estimates. They now expect a net loss of $(0.28) per share for 2015, $(0.12) per share for 2016, and $(0.04) per share for 2017. Read more: www.benzinga.com/analyst-ratings/analyst-color/15/05/5498649/mannkind-facing-low-profitability-and-delayed-profits-as#ixzz3ZyItptnV
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2015 19:23:03 GMT -5
No. This is the latest assault: Goldman Sachs Reaffirms “Sell” Rating for MannKind (MNKD) May 12th, 2015 • 0 comments • Filed Under • by ABMN Staff Tweet MannKind (NASDAQ:MNKD)‘s stock had its “sell” rating reiterated by research analysts at Goldman Sachs in a report released on Tuesday. They currently have a $2.00 price objective on the stock, down from their previous price objective of $3.00. Goldman Sachs’ price objective would indicate a potential downside of 45.21% from the company’s current price. MannKind (NASDAQ:MNKD) traded up 0.55% during mid-day trading on Tuesday, hitting $3.65. The stock had a trading volume of 8,245,303 shares. MannKind has a one year low of $3.46 and a one year high of $11.48. The stock has a 50-day moving average of $4. and a 200-day moving average of $5.. The company’s market cap is $1.45 billion. MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, May 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). During the same quarter in the previous year, the company posted ($0.14) earnings per share. On average, analysts predict that MannKind will post $-0.34 earnings per share for the current fiscal year. A number of other analysts have also recently weighed in on MNKD. Analysts at Jefferies Group reiterated a “buy” rating and set a $9.00 price target on shares of MannKind in a research note on Tuesday. Analysts at JPMorgan Chase & Co. downgraded shares of MannKind from a “neutral” rating to an “underweight” rating and lowered their price target for the stock from $7.00 to $4.00 in a research note on Monday. Analysts at MLV & Co. lowered their price target on shares of MannKind from $7.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday. Finally, analysts at Piper Jaffray initiated coverage on shares of MannKind in a research note on Friday. They set a “hold” rating and a $3.50 price target on the stock. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.06. MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The Company’s product candidate is AFREZZA which is an ultra rapid-acting insulin that is intended to improve glycemic control in adults with type 1 or type 2 diabetes. Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with Analyst Ratings Network's FREE daily email newsletter. GS's BS was out yesterday. We will see how many of their 600k shares they used to bury the SP at least thru the end of March in a few days when they are required to report.
|
|
|
Post by tchalaa on May 15, 2015 8:44:33 GMT -5
Jefferies affirms MannKind (Nasdaq: MNKD) at Buy with a price target of $9 folloinwg a recent Afrezza survey. Analyst Shaunak Deepak said Jefferies surveyed 56 endocrinologists and primary care physicians about their expected use of Afrezza for diabetes. Deepak commented, "In screening physicians, we found that 35 percent did not know about Afrezza. Those that did, however, expected to use Afrezza more frequently than we had expected, especially among Type 1 diabetics." On reasoning behind such a low launch, Deepak said, "Ignorance is a big factor: of the 120 physicians screened for this survey, 35 percent were not familiar with Afrezza. Combined with the 8 percent who knew about Afrezza but did not expect to prescribe it, this suggests nearly half of potential prescribers are not currently writing Afrezza scripts. Indeed, only 12 doctors surveyed had written a prescription for Afrezza. Separately, in keeping with MNKD’s 1Q commentary that lung function testing was a gating factor for Afrezza uptake, prescribers who did not own a spirometer rated the test a 5/5 burden, compared to a 2.5/5 burden for those who did." But, Deepak maintains a Buy rating, commenting, "Only a tenth of doctors screened had written an Afrezza script, we see MNKD’s efforts to expand access to spirometers and begin advertising in 3Q as key catalysts for uptake. With advertising, we expect the eventual rate of non-prescribers will fall closer to 12 percent. The 2015-2017 Afrezza use numbers implied by our survey suggest penetration rates nearly four times higher than we had previously modeled, and a $37 PT. To account for potential overreporting by surveyed physicians, we have discounted reported penetration rates by 70 percent and assumed that the reported 2017 penetration is a stand-in for peak." www.streetinsider.com/Analyst+Comments/Jefferies+Believes+Additional+Efforts+by+MannKind+%28MNKD%29+to+Expand+Afrezza+Could+Provide+Upside/10565885.html
|
|
|
Post by compound26 on May 15, 2015 8:49:51 GMT -5
Jefferies affirms MannKind (Nasdaq: MNKD) at Buy with a price target of $9 folloinwg a recent Afrezza survey. Analyst Shaunak Deepak said Jefferies surveyed 56 endocrinologists and primary care physicians about their expected use of Afrezza for diabetes. Deepak commented, "In screening physicians, we found that 35 percent did not know about Afrezza. Those that did, however, expected to use Afrezza more frequently than we had expected, especially among Type 1 diabetics." On reasoning behind such a low launch, Deepak said, "Ignorance is a big factor: of the 120 physicians screened for this survey, 35 percent were not familiar with Afrezza. Combined with the 8 percent who knew about Afrezza but did not expect to prescribe it, this suggests nearly half of potential prescribers are not currently writing Afrezza scripts. Indeed, only 12 doctors surveyed had written a prescription for Afrezza. Separately, in keeping with MNKD’s 1Q commentary that lung function testing was a gating factor for Afrezza uptake, prescribers who did not own a spirometer rated the test a 5/5 burden, compared to a 2.5/5 burden for those who did." But, Deepak maintains a Buy rating, commenting, "Only a tenth of doctors screened had written an Afrezza script, we see MNKD’s efforts to expand access to spirometers and begin advertising in 3Q as key catalysts for uptake. With advertising, we expect the eventual rate of non-prescribers will fall closer to 12 percent. The 2015-2017 Afrezza use numbers implied by our survey suggest penetration rates nearly four times higher than we had previously modeled, and a $37 PT. To account for potential overreporting by surveyed physicians, we have discounted reported penetration rates by 70 percent and assumed that the reported 2017 penetration is a stand-in for peak." www.streetinsider.com/Analyst+Comments/Jefferies+Believes+Additional+Efforts+by+MannKind+%28MNKD%29+to+Expand+Afrezza+Could+Provide+Upside/10565885.htmlIt think they meant to say "Analyst Shaunak Deepak said Jefferies surveyed 56 endocrinologists and 64 primary care physicians about their expected use of Afrezza for diabetes" as the article refers to "120 physicians screened for this survey" later.
|
|
|
Post by compound26 on May 15, 2015 8:53:45 GMT -5
Jefferies affirms MannKind (Nasdaq: MNKD) at Buy with a price target of $9 folloinwg a recent Afrezza survey. Analyst Shaunak Deepak said Jefferies surveyed 56 endocrinologists and primary care physicians about their expected use of Afrezza for diabetes. Deepak commented, "In screening physicians, we found that 35 percent did not know about Afrezza. Those that did, however, expected to use Afrezza more frequently than we had expected, especially among Type 1 diabetics." On reasoning behind such a low launch, Deepak said, "Ignorance is a big factor: of the 120 physicians screened for this survey, 35 percent were not familiar with Afrezza. Combined with the 8 percent who knew about Afrezza but did not expect to prescribe it, this suggests nearly half of potential prescribers are not currently writing Afrezza scripts. Indeed, only 12 doctors surveyed had written a prescription for Afrezza. Separately, in keeping with MNKD’s 1Q commentary that lung function testing was a gating factor for Afrezza uptake, prescribers who did not own a spirometer rated the test a 5/5 burden, compared to a 2.5/5 burden for those who did." But, Deepak maintains a Buy rating, commenting, "Only a tenth of doctors screened had written an Afrezza script, we see MNKD’s efforts to expand access to spirometers and begin advertising in 3Q as key catalysts for uptake. With advertising, we expect the eventual rate of non-prescribers will fall closer to 12 percent. The 2015-2017 Afrezza use numbers implied by our survey suggest penetration rates nearly four times higher than we had previously modeled, and a $37 PT. To account for potential overreporting by surveyed physicians, we have discounted reported penetration rates by 70 percent and assumed that the reported 2017 penetration is a stand-in for peak." www.streetinsider.com/Analyst+Comments/Jefferies+Believes+Additional+Efforts+by+MannKind+%28MNKD%29+to+Expand+Afrezza+Could+Provide+Upside/10565885.htmlReally like their report. Note that last paragraph: With advertising, we expect the eventual rate of non-prescribers will fall closer to 12 percent. The 2015-2017 Afrezza use numbers implied by our survey suggest penetration rates nearly four times higher than we had previously modeled, and a $37 PT. To account for potential overreporting by surveyed physicians, we have discounted reported penetration rates by 70 percent and assumed that the reported 2017 penetration is a stand-in for peak.
|
|
|
Post by trenddiver on May 18, 2015 17:52:22 GMT -5
Is there a link to the recent Jeffries research report?
|
|
|
Post by bullshares on Jun 4, 2015 20:09:54 GMT -5
|
|
|
Post by mannmade on Jun 8, 2015 21:51:40 GMT -5
finance.yahoo.com/news/mannkind-mnkd-worth-look-stock-134601474.htmlMannKind (MNKD) Worth a Look: Stock Adds 5.7% in Session - Tale of the Tape MannKind Corp. (MNKD) was a big mover last session, as the company saw its shares rise roughly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.63 to $5.79 in the past one-month time frame. None of the estimates for this med-biomed/gene stock were revised over the past 7 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future. MannKind currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
|
|
|
Post by mannmade on Jun 8, 2015 21:54:35 GMT -5
|
|
|
Post by johnford on Jun 9, 2015 8:26:57 GMT -5
|
|
|
Post by liane on Jun 9, 2015 11:40:03 GMT -5
From RBC Capital
June 9, 2015 MannKind Corporation SNY seemingly committed so far; selling effort to pick up in 2H:15
Neutral/ modest positive – Discussion was modest but SNY plans a more direct patient focus in second half.
SNY’s update at ADA included Afrezza where it highlighted selling efforts will pick up in second-half. We would have appreciated greater focus but given investments and plans for second half, SNY appears committed to Afrezza for now. What matters still is: 1) the growth trajectory in prescriptions 2) hurdles getting worked out, 3) whether patients will demand Afrezza, and 4) SNY’s commitment in 2015 and 2016. Initial launch effort classified as ‘moderate’; focused on awareness. The slide title had the words ‘targeted U.S. launch’ and ‘build awareness’ reflecting SNY’s focus on diabetes specialists and high prescribes who covered only 50% of the diabetes market. Next phase targeting patients, improving access, increasing awareness. SNY expected Afrezza to be a tier 3 benefit and the goal is to remove restrictions. It appears contract discussions with plans are ongoing. Planned second-half activities include: 1) print and direct-to-consumer program starting within weeks, 2) a patient support program, 3) an Afrezza coach program, 4) Speaker bureau and peer-to-peer education, 5) Publication of Phase III data, and 6) launch of the 12 unit dose late in 3Q:15. Data a focus too though we await new clinical studies to start. SNY highlighted Afrezza’s distinct PK/ PD profile where peak insulin activity occurs in 15 minutes with rapid decrease in insulin activity. This was previously a differentiating characteristic highlighted by MNKD and according to SNY customers who understand PK appreciate this. We believe in addition to plans for patient outreach the start of a clinical program for Afrezza would be sign of further SNY commitment and continue to await plans. Goal is for both new and more intense therapy patients; prescription data still low but growing. SNY expects both new patients and those who need more intense anti-diabetes therapy to benefit from Afrezza. While prescription data is far from reflecting commercial success at this time, the point is that it has been increasing, which is a trend that should pick up based on SNY’s comments on additional outreach in 2H:15.
|
|